TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has provided an update.
Shandong Xinhua Pharmaceutical Company Limited has announced the approval of its marketing application for Vonoprazan Fumarate, a chemical active pharmaceutical ingredient used to treat reflux esophagitis. This approval, granted by the National Medical Products Administration, positions the product within China’s public medical institutions, where related sales reached approximately RMB 825 million in 2024, indicating significant market potential and impact for the company.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, primarily involved in the production and marketing of chemical drugs. The company focuses on the development of active pharmaceutical ingredients, with a market emphasis on products listed in the National Drug Catalogue for Basic Medical Insurance.
Average Trading Volume: 2,158,245
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.8B
See more insights into 0719 stock on TipRanks’ Stock Analysis page.